Cediranib is a pan-VEGFR inhibitor that displays anticancer chemotherapeutic and anti-angiogenic activities. Cediranib is currently in clinical trials and displays activity against a wide variety of cancers. In an animal model of intestinal cancer, cediranib decreases lesion number and polyp size, and in a separate animal model of brain metastasis, cediranib decreases tumor vascular bed volume.
| Cas No. | 288383-20-0 |
|---|---|
| Purity | ≥98% |
| Formula | C25H27FN4O3 |
| Formula Wt. | 450.51 |
| IUPAC Name | 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline |
| Synonym | AZD2171 |
| Solubility | DMSO to 90 mg/ml |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | C1613 Info Sheet PDF |
|---|
Kummar S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol. 2013 Jun 20;31(18):2296-302. PMID: 23630200.
JuanYin J, Tracy K, Zhang L, et al. Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin Exp Metastasis. 2009;26(5):403-14. PMID: 19277878.
Goodlad RA, Ryan AJ, Wedge SR, et al. Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis. 2006 Oct;27(10):2133-9. PMID: 16782971.
